Literature DB >> 25764010

Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.

Umut Sabri Kasapoglu1, Sibel Arınç2, Sinem Gungor2, Ilim Irmak3, Pinar Guney2, Ferda Aksoy4, Dilek Bandak5, Armagan Hazar2.   

Abstract

BACKGROUND AND AIMS: Lung cancer is the most common cause of malignant pleural effusions (MPEs). For patients with lung cancer and MPE, median survival is only 3-4 months. The aim of this study was to evaluate lung cancer patients with MPE by clinical and laboratory findings on admission, and determine 2-year survival rate and prognostic factors.
METHODS: Between 2008 and 2011, we examined 199 cases of non-small cell lung carcinoma with MPE. Demographic factors of patients, tumor characteristics, treatment delivered and laboratory parameters affecting prognosis were evaluated. Survival rates were estimated by Kaplan-Meier method. Significance of each prognostic factors selected by univariate analysis were confirmed using Cox regression model.
RESULTS: The study included 139 (69.8%) male and 60 (30.2%) female patients with a median age of 64 (30-85) years. Median overall survival was 4.4 months. Adenocarcinoma was the leading cause of MPE with 80.4%. A univariate analysis showed that factors affecting mortality included gender (P < 0.001), MPE with distant metastasis (P = 0.025), lower serum albumin (P < 0.0001), lower pleural protein (P < 0.0001), increased serum lactate dehydrogenase (P = 0.003), increased serum C-reactive protein (CRP) (P < 0.0001), increased white blood cells (P < 0.0001), histopathological type (P = 0.004) and treatment decision (P < 0.0001). A multivariate analysis revealed that patients who had high level of serum CRP (P = 0.017), lower serum albumin (P = 0.009) and lower pleural protein (P = 0.003), MPE with distant metastasis (P = 0.003) and those who were chemotherapy naive (P < 0.0001) had shorter survival.
CONCLUSION: High level of serum CRP, lower serum albumin and lower pleural protein, MPE with distant metastasis were most important prognostic factors for non-small cell lung carcinoma in patients with MPEs.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  distant metastasis; malignant pleural effusion; non-small cell lung cancer; prognostic factors; survival

Mesh:

Substances:

Year:  2015        PMID: 25764010     DOI: 10.1111/crj.12292

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  17 in total

1.  Sarcopenia in patients with malignant pleural effusion: impact on symptoms, health status, and response to hospitalization.

Authors:  Janet Rodríguez-Torres; Laura López-López; Irene Cabrera-Martos; Gerald Valenza-Demet; Lawrence P Cahalin; Marie Carmen Valenza
Journal:  Support Care Cancer       Date:  2019-04-03       Impact factor: 3.603

2.  Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.

Authors:  Mei Feng; Jing Zhu; Liqun Liang; Ni Zeng; Yanqiu Wu; Chun Wan; Yongchun Shen; Fuqiang Wen
Journal:  Int J Clin Oncol       Date:  2016-12-18       Impact factor: 3.402

3.  Elevated RABEX-5 expression predicts poor prognosis in non-small-cell lung cancer.

Authors:  Fuliang Zhang; Yingjie Jia; Fanming Kong; Guohua Hu; Qiling Cai; Tongbai Xu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

4.  Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.

Authors:  Sofia Molina; Gabriela Martinez-Zayas; Paula V Sainz; Cheuk H Leung; Liang Li; Horiana B Grosu; Roberto Adachi; David E Ost
Journal:  Chest       Date:  2021-05-11       Impact factor: 10.262

5.  Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.

Authors:  Ilija Nenadić; Jeanine Staber; Susanne Dreier; Guus Simons; Verena Schildgen; Michael Brockmann; Oliver Schildgen
Journal:  Cancers (Basel)       Date:  2017-07-11       Impact factor: 6.639

6.  Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.

Authors:  Fanming Kong; Fangfang Gao; Jun Chen; Yiyu Sun; Ying Zhang; Honggen Liu; Xiaojiang Li; PeiYing Yang; Rongxiu Zheng; Geli Liu; Yingjie Jia
Journal:  Oncotarget       Date:  2016-08-30

7.  Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions.

Authors:  Carl-Olof Hillerdal; Rita Ötvös; Tünde Szatmári; Sulaf Abd Own; Gunnar Hillerdal; Åsa-Lena Dackland; Katalin Dobra; Anders Hjerpe
Journal:  Oncotarget       Date:  2017-09-15

8.  Suppression of Circular RNA Hsa_circ_0109320 Attenuates Non-Small Cell Lung Cancer Progression via MiR-595/E2F7 Axis.

Authors:  Qiaohong Bai; Li Li; Futao Chen; Jiang Zhu; Lifeng Cao; Yang Yang; Fukuan Zhong
Journal:  Med Sci Monit       Date:  2020-06-08

9.  Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.

Authors:  Akash Verma; Chee Kiang Phua; Wen Yuan Sim; Reyes Elmer Algoso; Kuan Sen Tee; Sennen J W Lew; Albert Y H Lim; Soon Keng Goh; Dessmon Y H Tai; Ai Ching Kor; Benjamin Ho; John Abisheganaden
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.

Authors:  Guo-Jun Lu; Cheng-Jie Shao; Yu Zhang; Yong-Yue Wei; Wei-Ping Xie; Hui Kong
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.